Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study*

Tanya Skamene, Michael Crump, Kerry J. Savage, Tony Reiman, John Kuruvilla, David Good, David LeBrun, Ralph M. Meyer, Laurie H. Sehn, Denis Soulières, Julie Stakiw, Nicole Laferriere, Stefano Luminari, Lois E. Shepherd, Marina Djurfeldt, Liting Zhu, Bingshu E. Chen, Annette E. Hay

Research output: Contribution to journalArticle

Abstract

Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy. Of the 619 patients with relapsed and refractory (R/R) aggressive lymphoma enrolled in the Canadian Cancer Trials Group LY.12 phase 3 trial, 59 (9.5%) had PTCL. Among these, 81% had advanced stage disease, 41% had an International Prognostic Score ≥3, and 41% were refractory to primary therapy. Within the PTCL cohort, the overall response rate after two cycles of salvage chemotherapy was 36%; no difference was observed between dexamethasone, cytarabine, cisplatin (10/30, 33%), and gemcitabine, cisplatin, dexamethasone (11/29, 38%) therapy. At one year, event-free survival (EFS) was 16% and overall survival (OS) was 28%. For PTCL patients, who received autologous stem cell transplant, two-year EFS and OS were 21% and 42%, respectively. Patients with PTCL had inferior OS (HR 0.49, p <.0001) and EFS (HR 0.53, p <.0001) compared to B-cell lymphoma. Outcomes for patients with R/R PTCL are poor with currently available therapies.

Original languageEnglish
Pages (from-to)2319-2327
Number of pages9
JournalLeukemia and Lymphoma
Volume58
Issue number10
DOIs
Publication statusPublished - Oct 3 2017

    Fingerprint

Keywords

  • autologous stem cell transplantation
  • randomized phase 3 clinical trial
  • relapse
  • salvage
  • T-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Skamene, T., Crump, M., Savage, K. J., Reiman, T., Kuruvilla, J., Good, D., LeBrun, D., Meyer, R. M., Sehn, L. H., Soulières, D., Stakiw, J., Laferriere, N., Luminari, S., Shepherd, L. E., Djurfeldt, M., Zhu, L., Chen, B. E., & Hay, A. E. (2017). Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study*. Leukemia and Lymphoma, 58(10), 2319-2327. https://doi.org/10.1080/10428194.2017.1312379